Takeda Pharms Am
1 products tracked · names used in filings: Takeda Pharms Am
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 28 Aug 2026🇺🇸 FDA approval
FDA approves Mimrylo (rusfertide acetate), a new medicine
Takeda Pharms Am; NDA220605; New molecular entity, Priority review; powder · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Mimrylo rusfertide acetate | Approved | 2026-08-28 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.